LY4100511 in Moderate-to-Severe Plaque Psoriasis

• LY4100511 200 mg BID

  LY4100511 200 mg administered orally twice daily for 12 weeks.

• LY4100511 400 mg BID

  LY4100511 400 mg administered orally twice daily for 12 weeks.

• LY4100511 800 mg QD

  LY4100511 800 mg administered orally once daily for 12 weeks, with matching placebo in the evening.

• Placebo BID

  Placebo administered orally twice daily for 12 weeks.

Primary

• Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index12 weeks

Secondary

• Percentage of Participants Achieving an sPGA Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement12 weeks

• Percentage of Participants Achieving ≥50% Reduction From Baseline in Psoriasis Area and Severity Index12 weeks

• Percentage of Participants Achieving ≥90% Reduction From Baseline in Psoriasis Area and Severity Index12 weeks

• Percentage of Participants Achieving ≥100% Reduction From Baseline in Psoriasis Area and Severity Index12 weeks

• Change From Baseline in PASI Score12 weeks

• Percent Change From Baseline in PASI Score12 weeks

• Change From Baseline in the Percentage of Body Surface Area Affected12 weeks

• Percent Change From Baseline in the Percentage of BSA Affected12 weeks